Please login to the form below
Mydayis
This page shows the latest Mydayis news and features for those working in and with pharma, biotech and healthcare.
Shire separates out neuroscience as it considers its future
The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the
Latest news
-
Shire claims FDA approval for slow-cooked ADHD drug
Mydayis will reach the US market in the third quarter of the year. ... After more than a decade, Shire has finally won approval in the US for its long-acting attention deficit hyperactivity disorder drug (ADHD) Mydayis.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- First trial of a vaccine against Alzheimer’s launches
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- AbbVie/Allergan merger faces renewed public opposition despite divestments
- AbbVie/Allergan's merger faces public opposition
- AstraZeneca officially opens new R&D facility in UK
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
